These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 25283266)
1. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H; Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266 [TBL] [Abstract][Full Text] [Related]
2. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H; Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366 [TBL] [Abstract][Full Text] [Related]
4. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640 [TBL] [Abstract][Full Text] [Related]
5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172 [TBL] [Abstract][Full Text] [Related]
6. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184 [TBL] [Abstract][Full Text] [Related]
7. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415 [TBL] [Abstract][Full Text] [Related]
8. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Miyake H; Harada KI; Ozono S; Fujisawa M Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522 [TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330 [TBL] [Abstract][Full Text] [Related]
10. Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. Mizuno R; Mikami S; Takamatsu K; Shinojima T; Kikuchi E; Oya M Jpn J Clin Oncol; 2017 Dec; 47(12):1170-1174. PubMed ID: 28977627 [TBL] [Abstract][Full Text] [Related]
11. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146 [TBL] [Abstract][Full Text] [Related]
13. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Rini BI; de La Motte Rouge T; Harzstark AL; Michaelson MD; Liu G; Grünwald V; Ingrosso A; Tortorici MA; Bycott P; Kim S; Bloom J; Motzer RJ Clin Genitourin Cancer; 2013 Jun; 11(2):107-14. PubMed ID: 23391371 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060 [TBL] [Abstract][Full Text] [Related]
15. Axitinib for the management of metastatic renal cell carcinoma. Escudier B; Gore M Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004 [TBL] [Abstract][Full Text] [Related]
16. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205 [TBL] [Abstract][Full Text] [Related]
17. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma. Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813 [TBL] [Abstract][Full Text] [Related]
18. Axitinib controlled metastatic renal cell carcinoma for 5 years. Takayama T; Nagata M; Kai F; Sugiyama T; Ozono S Jpn J Clin Oncol; 2013 Jul; 43(7):747-51. PubMed ID: 23667154 [TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431 [TBL] [Abstract][Full Text] [Related]